Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUATTRO: FOLFOXIRI plus Bevacizumab in mCRC
NCT02246049Phase 2Completed
- Sponsor
- EPS Corporation
- Start
- May 2014
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by EPS Corporation. Started May 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02246049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246049.